Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CD3+/CD19+ cell-depleted unrelated or partially matched donor-derived allogeneic peripheral blood stem cells

A preparation of allogeneic peripheral blood stem cells (PBSCs) from an unrelated or partially matched related donor that have been selectively depleted of CD3-positive (CD3+) T cells and CD19-positive (CD19+) B cells via leukapheresis with potential immune reconstituting activity. The CD3+/CD19+ cell-depleted PBSCs are used for allogeneic hematopoietic cell transplantation (HCT) and may allow for rapid and sustained engraftment, immune reconstitution, and may prevent or reduce graft-versus-host disease (GvHD) and Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disorders.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CD3+ and CD19+ cell-depleted allogeneic PBSCs derived from an unrelated or partially matched donor
CD3+ T-cell-depleted/CD19+ B-cell-depleted unrelated or partially matched donor-derived allogeneic peripheral blood stem cells
CD3+/CD19+ cell-depleted unrelated or partially matched donor-derived allogeneic PBSCs
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search